6 results on '"Gil Sacaluga L."'
Search Results
2. Estudio prospectivo aleatorizado multicéntrico para demostrar los beneficios de la hemodiálisis sin acetato (con citrato): Estudio ABC-treat. Efecto agudo del citrato
- Author
-
de Sequera Ortiz, Patricia, Pérez García, Rafael, Molina Nuñez, Manuel, Muñoz González, Rosa Inés, Álvarez Fernández, Gracia, Mérida Herrero, Eva, Camba Caride, María Jesús, Blázquez Collado, Luís Alberto, Alcaide Lara, M. Paz, Echarri Carrillo, Rocío, Gallardo, I., Hernández Martínez, E., Otero González, A., Sánchez Heras, M., de Arriba de la Fuente, G., Gil Sacaluga, L., Cirugeda García, A., and Barrio Lucía, V.
- Published
- 2019
- Full Text
- View/download PDF
3. Association of a single nucleotide polymorphism combination pattern of the Klotho gene with non-cardiovascular death in patients with chronic kidney disease
- Author
-
Cambray S., Bermudez-Lopez M., Bozic M., Valdivielso J.M., Castro E., María V., Molí T., Vidal T., Soria M., Aladrén Regidor Ma.J., Almirall J., Ponz E., Arteaga Coloma J., Bajo Rubio Ma.A., Belart Rodríguez M., Gascón A., Bover Sanjuan J., Puigvert F., Bronsoms Artero J., Cabezuelo Romero J.B., Muray Cases S., Calviño Varela J., Caro Acevedo P., Carreras Bassa J., Cases Amenós A., Massó Jiménez E., Moreno López R., Cigarrán Guldris S., López Prieto S., Comas Mongay L., Comerma I., Compte Jové Ma.T., Cuberes Izquierdo M., de Álvaro F., Hevia Ojanguren C., de Arriba de la Fuente G., del Pino y Pino Ma.D., Diaz-Tejeiro Izquierdo R., Hormigos A., Dotori M., Duarte V., Estupiñan Torres S., Fernández Reyes Ma.J., Fernández Rodríguez Ma.L., Fernández G., Galán Serrano A., García Cantón C., García Herrera A.L., García Mena M., Gil Sacaluga L., Aguilar M., Górriz J.L., Huarte Loza E., Lerma J.L., Liebana Cañada A., Marín Álvarez J.P., Martín Alemany N., Martín García J., Martínez Castelao A., Martínez Villaescusa M., Martínez I., Moina Eguren I., Moreno Los Huertos S., Mouzo Mirco R., Munar Vila A., Muñoz Díaz A.B., Navarro González J.F., Nieto J., Carreño A., Novoa Fernández E., Ortiz A., Fernandez B., Paraíso V., Pérez Fontán M., Peris Domingo A., Piñera Haces C., Prados Garrido Ma.D., Prieto Velasco M., Puig Marí C., Rivera Gorrín M., Rubio E., Ruiz P., Salgueira Lazo M., Martínez Puerto A.I., Sánchez Tomero J.A., Sánchez J.E., Sans Lorman R., Saracho R., Sarrias M., Serón D., Soler M.J., Barrios C., Sousa F., Toran D., Tornero Molina F., Usón Carrasco J.J., Valera Cortes I., Vilaprinyo del Perugia Ma.M., Ruiz V., Pallarés V., Altozano C.S., Ródenas M.A., Sanitaria de Arán I.G.G.Á.B., Gil F.A., Criado E.G., Belinchón R.D., Fernández Toro J.Ma., and Antonio J.
- Subjects
cardiovascular risk ,genetic association ,adult ,genotype ,allele ,chronic kidney failure ,cohort analysis ,major clinical study ,Klotho protein ,Article ,homozygote ,aged ,cause of death ,female ,multicenter study ,male ,priority journal ,cardiovascular mortality ,single nucleotide polymorphism ,follow up ,human ,prospective study - Abstract
Background. Chronic kidney disease (CKD) is associated with an elevated risk of all-cause mortality, with cardiovascular death being extensively investigated. However, non-cardiovascular mortality represents the biggest percentage, showing an evident increase in recent years. Klotho is a gene highly expressed in the kidney, with a clear influence on lifespan. Low levels of Klotho have been linked to CKD progression and adverse outcomes. Single nucleotide polymorphisms (SNPs) of the Klotho gene have been associated with several diseases, but studies investigating the association of Klotho SNPs with noncardiovascular death in CKD populations are lacking. Methods. The main aim of this study was to assess whether 11 Klotho SNPs were associated with non-cardiovascular death in a subpopulation of the National Observatory of Atherosclerosis in Nephrology (NEFRONA) study (n ¼ 2185 CKD patients). Results. After 48 months of follow-up, 62 cardiovascular deaths and 108 non-cardiovascular deaths were recorded. We identified a high non-cardiovascular death risk combination of SNPs corresponding to individuals carrying the most frequent allele (G) at rs562020, the rare allele (C) at rs2283368 and homozygotes for the rare allele (G) at rs2320762 (rs562020 GG/AG þ rs2283368 CC/CT þ rs2320762 GG). Among the patients with the three SNPs genotyped (n ¼ 1016), 75 (7.4%) showed this combination. Furthermore, 95 (9.3%) patients showed a low-risk combination carrying all the opposite genotypes (rs562020 AA þ rs2283368 TT þ rs2320762 GT/TT). All the other combinations [n ¼ 846 (83.3%)] were considered as normal risk. Using competing risk regression analysis, we confirmed that the proposed combinations are independently associated with a higher fhazard ratio [HR] 3.28 [confidence interval (CI) 1.51-7.12]g and lower [HR 6 × 10-6 (95% CI 3.3 × 10-7-1.1 × 10-5)] risk of suffering a non-cardiovascular death in the CKD population of the NEFRONA cohort compared with patients with the normal-risk combination. Conclusions. Determination of three SNPs of the Klotho gene could help in the prediction of non-cardiovascular death in CKD. © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Published
- 2020
- Full Text
- View/download PDF
4. In response to the article "The challenge of cardiovascular disease in patients with chronic kidney disease".
- Author
-
Arjona Barrionuevo JD, Gil Sacaluga L, Gonzales Vargas-Machuca M, Guerrero Márquez F, Sainz Hidalgo I, López Mendoza M, and Gentil Govantes MA
- Subjects
- Humans, Cardiovascular Diseases etiology, Renal Insufficiency, Chronic complications, Kidney Failure, Chronic
- Published
- 2023
- Full Text
- View/download PDF
5. Prognosis Factors of Patients Undergoing Renal Replacement Therapy.
- Author
-
Muñoz-Terol JM, Rocha JL, Castro-de la Nuez P, Egea-Guerrero JJ, Gil-Sacaluga L, García-Cabrera E, and Vilches-Arenas A
- Abstract
Background: Survival in patients with end-stage kidney disease (ESKD) on renal replacement therapy (RRT) is less than that of the general population of the same age, and depends on patient factors, the medical care received, and the type of RRT used. The objective of this study is to analyze the factors associated with survival in patients undergoing RRT., Methods: We conducted a retrospective observational study of adult patients with an incident of ESKD on RRT in Andalusia from 1 January 2008 to 31 December 2018. Patient characteristics, nephrological care received, and survival from the beginning of RRT were evaluated. A survival model for the patient was developed according to the variables studied., Results: A total of 11,551 patients were included. Median survival was 6.8 years (95% CI (6.6; 7.0)). After starting RRT, survival at one year and five years was 88.7% (95% CI (88.1; 89.3)) and 59.4% (95% CI (58.4; 60.4)), respectively. Age, initial comorbidity, diabetic nephropathy, and a venous catheter were independent risk factors. However, non-urgent initiation of RRT and follow-up in consultations for more than six months had a protective effect. It was identified that renal transplantation (RT) was the most influential independent factor in patient survival, with a risk ratio of 0.13 (95% CI (0.11; 0.14))., Conclusions: The receiving of a kidney transplant was the most beneficial modifiable factor in the survival of incident patients on RRT. We consider that the mortality of the renal replacement treatment should be adjusted, taking into account both modifiable and nonmodifiable factors to achieve a more precise and comparable interpretation.
- Published
- 2023
- Full Text
- View/download PDF
6. Thermal disinfection in hemodialysis using the A0 concept as dispenser.
- Author
-
Toapanta Gaibor NG, Gil Sacaluga L, de la Cerda Ojeda F, Molas Cotén JR, and Salgueira Lazo M
- Subjects
- Colony Count, Microbial methods, Disinfection standards, Hepatitis B virus, Humans, Retrospective Studies, Time Factors, Water Microbiology, Disinfection methods, Hemodialysis Solutions standards, Hot Temperature, Renal Dialysis instrumentation, Renal Insufficiency, Chronic therapy, Water standards
- Abstract
Patients with chronic kidney disease in the hemodialysis program are exposed to large amounts of water, as this constitutes about 96% of the dialysis fluid. It is known that the use of better quality water decreases the state of chronic inflammation in dialysis patients. Disinfection as part of water treatment plays an important role in meeting the established quality standards; currently, heat disinfection is highly recommended, however its dose is not clearly established in the literature. The objective of this review is to know what is available in the literature on the dose of heat disinfection that should be used in hemodialysis and to present our experience with this method at a set dose of 12.000 A
0 ., (Copyright © 2019 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.